Cephalon, Inc.

89Bio, Inc.

Cancer Research Technology Limited

Janssen Pharmaceutica Nv

University of Utah Research Foundation

University of Hawai'i

Craig A Zificsak

Bruce D Dorsey

Robert L Hudkins

Allison L Zulli

Linda Weinberg

Nadine C Becknell

Dimitar B Gotchev

Reddeppa Reddy Dandu

Jay P Theroff

Gregory R Ott

Eugen F Mesaros

Henry Joseph Breslin

Benjamin J Dugan

Karen L Milkiewicz

Rabindranath Tripathy

James L Diebold

Diane E Gingrich

Theodore L Underiner

Gregory J Wells

Melody McWherter

Joseph Lisko

Emma L Morris

Katherine M Fowler

Christelle N Soudy

Tho V Thieu

Nathaniel J T Monck

Gregoire A Pave

Ikeoluwa Olowoye

Tao Guo

Ming Tao

Keith S Learn

David B Whitman

Gulzar Ahmed

Douglas A Pippin

Matthew A Curry

Rong-qiang Liu

Jonathan R A Roffey

Jason Burke

Daming Feng

Koc-Kan Ho

Sankar Chatterjee

Kurt A Josef

Dennis J Hlasta

Derek D Dunn

Greg A Hostetler

Babu G Sundar

Jason C Wagner

Ted Underiner

Jonathan R Roffey

Scott K Kuwada

Rachael Hunter

Ming You

Nathaniel Jt Monck

Joseph G Lisko

Jonathan RA Roffey

Karen Milkiewicz

Adolph Bohnstedt

Bruce Dorsey

Jonathan Parrish

Rong-Qiang Liu

Henry J Breslin

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses.

Spiropiperidine derivatives

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

Substituted 4-benzyl and 4-benzoyl piperidine derivates

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses.

1,4-substituted piperidine derivatives

Described herein are spiropiperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described spiropiperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described spiropiperidine compounds and synthetic intermediates that are useful in those syntheses. 

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds. Also described herein are methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. 

Substituted 4-benzyl and 4-benzoyl piperidine derivatives

Described herein are 1,4-substituted piperidine compounds according to Formula I that have demonstrated activity as fatty acid synthase inhibitors. Also described herein are pharmaceutical compositions containing the described 1,4-substituted piperidine compounds, and methods of treating diseases mediated by fatty acid synthase, by administering one or more of the compounds or pharmaceutical formulations described herein. Also described herein are methods of synthesizing the compounds described, including the described 1,4-substituted piperidine compounds and synthetic intermediates useful in those syntheses. 

The present application provides a compound of formula (I) and/or a salt thereof, wherein R, G, and X are as defined herein. A compound of formula (I) and/or its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders. Compositions comprising a compound of Formula (I) and/or a salt thereof are also provided.

Azaquinazoline inhibitors of atypical protein kinase C

The present application provides azaquinazoline compounds as defined herein. This application further describes compositions comprising the same. These azaquinazoline compounds and their salts have atypical protein kinase C ('aPKC') inhibitory activity, and may be used to treat proliferative disorders.

Azaquinazoline inhibitors of Atypical protein Kinase C

The present application provides a compound of formula (I) or a salt thereof, wherein R, R, R, G, and X are as defined herein. This application further describes compositions comprising the same. Compounds of formula (I) and their salts have aPKC inhibitory activity, and may be used to treat proliferative diseases.

Compounds of formula II are described: wherein D, n, R, R, and Rare as herein defined, along with pharmaceutical compositions and methods of using compounds of formula II for treating or reducing the risk of peritoneal carcinomatosis in a patient.

Substituted aromatic sulfur compounds and methods of their use

Growing community of inventors

Downingtown, PA, United States of America

Craig A Zificsak